Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG).
Department of Pediatric, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
Department of Internal Medicine, Emam Khomeini Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
- Published Article
Biologics : targets & therapy
- Publication Date
Jan 01, 2019
We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 10/23/2019 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/31239637